<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156425">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939392</url>
  </required_header>
  <id_info>
    <org_study_id>CP-1003</org_study_id>
    <nct_id>NCT01939392</nct_id>
  </id_info>
  <brief_title>Rapid Renal Sympathetic Denervation for Resistant Hypertension II</brief_title>
  <acronym>RAPID II</acronym>
  <official_title>Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Covidien</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Covidien</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global, multi-center, prospective, randomized, controlled study of the safety and
      effectiveness of renal denervation with the OneShot Renal Denervation System in patients
      with uncontrolled hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Major adverse event (MAE) rate through 30 days post randomization</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in office systolic blood pressure (SBP) from baseline to 6 months post-randomization</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Procedural Safety</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic procedural safety</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in SBP by &gt;10 mmHg at 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in office SBP and diastolic blood pressure (DBP) from baseline to follow-up visits</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">253</enrollment>
  <condition>Resistant Hypertension</condition>
  <condition>Uncontrolled Hypertension</condition>
  <condition>Renal Artery Ablation</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to the control arm will be maintained on antihypertensive medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation (OneShot™ Renal Denervation System)</intervention_name>
    <arm_group_label>Renal Denervation</arm_group_label>
    <other_name>OneShot Ablation system</other_name>
    <other_name>Catheter-based renal denervation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individual has a systolic blood pressure ≥ 160 mmHg based on an average of three
             office blood pressure readings.

          -  Stable drug regimen including three or more anti-hypertensive medications including a
             diuretic

        Exclusion Criteria:

          -  Renal anatomy unsuitable for treatment

          -  Presence of hemodynamically significant valvular heart disease for which reduction of
             blood pressure would be considered hazardous

          -  Patient has Type I diabetes

          -  Has scheduled or planned surgery within the next 6 months

          -  Individual is pregnant nursing or plans to be pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Scheinert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park-Krankenhaus Liepzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guiseppe Mancia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita Minano-Bicocca, Ospedale San Gerardo di Monza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Krygier, MBA</last_name>
    <email>karen.krygier@covidien.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 6, 2013</lastchanged_date>
  <firstreceived_date>September 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resistant hypertension</keyword>
  <keyword>Uncontrolled hypertension</keyword>
  <keyword>Renal artery ablation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
